FDA Inspection 1229553 — Syngene USA Inc.
The FDA completed an inspection of Syngene USA Inc. on February 8, 2024 in Baltimore, MD. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 8, 2024
- Fiscal Year
- 2024
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Baltimore, MD (United States)